On September 1, 2026 Styx Biotechnologies, Inc., a San Diego-based biotechnology company developing next-generation antibody-drug conjugates (ADCs) for solid tumors, reported a strategic agreement with ZoeNCure Therapeutics Pvt. Ltd. to accelerate selected Styx ADC programs toward first-in-human clinical studies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the agreement, Styx will receive an upfront payment and additional milestone-based payments tied to development progress. In exchange, ZoeNCure will provide development capital and leverage its specialized clinical infrastructure to execute early-phase clinical studies. Additional financial terms were not disclosed.
The collaboration provides Styx with a capital-efficient pathway for selected ADC assets while preserving opportunities for broader global clinical development and strategic partnering. The agreement supports coordinated preclinical, CMC, regulatory, and clinical activities, enabling Styx to advance key pipeline programs without assuming the full capital burden typically required for early clinical development.
"This agreement represents an important step in our strategy to advance our most promising ADC programs efficiently while preserving long-term value," said Ashutosh Tiwari, PhD, Chief Executive Officer of Styx Biotechnologies. "This collaboration creates a capital-efficient path to first-in-human development by allowing Styx to clinically de-risk selected programs while preserving our ability to pursue broader global development and partnering opportunities."
Styx is developing a pipeline of novel ADCs across multiple solid tumor indications, including liver, gastric and rare cancers. Its programs combine clinically relevant tumor biology with differentiated antibody, and dual-payload strategies designed to address therapeutic index, tumor heterogeneity, and treatment resistance. The collaboration allows Styx to advance these lead assets toward clinical validation while continuing to invest in its broader portfolio. The companies believe this approach can shorten development timelines, improve capital efficiency and establish a strong foundation for subsequent global clinical development.
(Press release, Styx Biotechnologies, SEP 1, 2026, View Source [SID1234670511])